Biogen to buy Reata Pharmaceuticals for $7B; key Republicans nix idea to give FDA a new authority

Taking stock of the drug industry, from the lab to the medicine chest

July 28, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Steven Senn/AP STAT+ | Biogen to acquire Reata Pharmaceuticals in $7 billion deal The transaction price of $172.50 per share is a nearly 60% premium from Reata's share price at Thursday's close. By Andrew Joseph and Adam Feuerstein STAT+ | AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field AstraZeneca will buy a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting the field. By Jason Mast STAT+ | Key Republicans nix idea to give FDA new power to regulate CBD Republicans insist that the FDA can regulate CBD like it would any other dietary supplement or food additive. By Nicholas Florko Anna Moneymaker/Getty Images STAT+ | House GOP offers new plan to stem drug shortages, including cancer drug shortages House Republicans have drafted legislation to address cancer and other drug shortages that differs significantly from Democrats' approach. By John Wilkerson STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Mental illness, drug addiction go hand in glove, Biden's drug czar tells lawmakers It's really important that the lawmakers address both mental health and social isolation to successfully tackle the drug-addiction crisis. By Simar Bajaj

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser